Jack Lin's questions to Zai Lab Ltd (ZLAB) leadership • Q2 2025
Question
Jack Lin from Morgan Stanley sought clarification on the data catalyst timeline for the DLL3 ADC, for both second-line and first-line treatment settings. He also asked for the company's view on recent policy updates regarding the ramp-up of commercial insurance in China and any potential implications for the commercial strategy of products like Optune.
Answer
Rafael Amado, President and Head of Global R&D, clarified that the DLL3 second-line data update is expected by year-end, with first-line data likely in early 2026. Josh Smiley, President & COO, commented that the policy trend toward expanded commercial insurance is encouraging. He noted it creates a valuable opportunity to drive sales for innovative drugs like Optune and others during the gap between regulatory approval and potential NRDL listing.